ECHINACOSIDE: Echinacea angustifolia extract

Echinacea angustifolia background

fig.1 - Echinacea angustifolia
commonly known as Narrow-leaved Purple Coneflower

Echinacea angustifolia is a herbaceous, flowering and perennial plant member of the Asteraceae family (fig.1).

Echinacea represents an important element of traditional medicine preparations in North America. The root of Echinacea is greatly valued by the ethnopharmacology and the sprouts and flowers activity was also known by American Indians. The most common species of Echinacea, in traditional remedies, are E. purpurea, E. pallida and E. angustifolia.

American Indians considered also Echinacea as a versatile herb that contributed to fight infections, increase appetite and strenghten the sexual male organ.
Echinacea angustifolia species is particularly well known nowadays for its anti-oxidant and scavenging properties. The most important active ingredient extracted from Echinacea angustifolia is the phenylpropanoid ECHINACOSIDE.

Echinacoside is a secondary metabolite produced by the plant as a difensive compound against pathogens. Echinacoside is a natural caffeic acid glycoside consisting of a trisaccharide formed by two glucose molecules and one rhamnose moiety (fig.2).
ABR developed a biotech platform for the production of Echinacoside using suspension cell culture of Echinacea angustifolia.




ECHINAN 4P - the product

fig.2 - Chemical structure of Echinacoside

ECHINAN 4P is the ABR commercial name of the active ingredient Echinacoside titrated at 4%, extracted and purified from Echinacea angustifolia suspension cell culture.
ECHINAN 4P is a Novel Food authorized ingredient.


Echinacoside - biological effects

Echinacoside has recently shown to possess neuroprotective effects. Additionally, Echinacoside was demonstrated to feature anti-inflammatory, antineoplastic, antiaging and immunomodulatory properties.

Clinical studies demonstrated the Echinacoside beneficial effects in:

  • Fighting flu and flu-like infections
  • Modulating immunosuppressive conditions
  • Reducing risk for medical complications in upper respiratory tract infections
  • Modulating the erythropoietin production without affecting red blood cells count

Scientific literature and preclinical and clinical data are freely available at ABR Reserved Area upon on-line registration.



Request for info and quote:

please contact info@abres.it for commercial enquiries or metabolites@abres.it for technical requests.




Manufactured under licensed technology from IRB S.p.A. – Altavilla Vicentina

-